Dramatic accumulation of triglycerides and precipitation of cardiac hemodynamic dysfunction during brief caloric restriction in transgenic myocardium expressing human calcium-independent phospholipase A2gamma.
Previously, we identified calcium-independent phospholipase A2gamma (iPLA2gamma) with multiple translation initiation sites and dual mitochondrial and peroxisomal localization motifs. To determine the role of iPLA2gamma in integrating lipid and energy metabolism, we generated transgenic mice containing the alpha-myosin heavy chain promoter (alphaMHC) placed proximally to the human iPLA2gamma coding sequence that resulted in cardiac myocyte-restricted expression of iPLA2gamma (TGiPLA2gamma). TGiPLA2gamma mice possessed multiple phenotypes including: 1) a dramatic approximately 35% reduction in myocardial phospholipid mass in both the fed and mildly fasted states; 2) a marked accumulation of triglycerides during brief caloric restriction that represented 50% of total myocardial lipid mass; and 3) acute fasting-induced hemodynamic dysfunction. Biochemical characterization of the TGiPLA2gamma protein expressed in cardiac myocytes demonstrated over 25 distinct isoforms by two-dimensional SDS-PAGE Western analysis. Immunohistochemistry identified iPLA2gamma in the peroxisomal and mitochondrial compartments in both wild type and transgenic myocardium. Electron microscopy revealed the presence of loosely packed and disorganized mitochondrial cristae in TGiPLA2gamma mice that were accompanied by defects in mitochondrial function. Moreover, markedly elevated levels of 1-hydroxyl-2-arachidonoyl-sn-glycero-3-phosphocholine and 1-hydroxyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine were prominent in the TGiPLA2gamma myocardium identifying the production of signaling metabolites by this enzyme in vivo. Collectively, these results identified the participation of iPLA2gamma in the remarkable lipid plasticity of myocardium, its role in generating signaling metabolites, and its prominent effects in modulating energy storage and utilization in myocardium in different metabolic contexts.
Mancuso
David J
DJ
Division of Bioorganic Chemistry and Molecular Pharmacology, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Han
Xianlin
X
Jenkins
Christopher M
CM
Lehman
John J
JJ
Sambandam
Nandakumar
N
Sims
Harold F
HF
Yang
Jingyue
J
Yan
Wei
W
Yang
Kui
K
Green
Karen
K
Abendschein
Dana R
DR
Saffitz
Jeffrey E
JE
Gross
Richard W
RW
D000818:Animals; D002118:Calcium / Q000378:metabolism*; D031204:Caloric Restriction; D009202:Cardiomyopathies / Q000235:genetics* / Q000473:pathology*; D005786:Gene Expression Regulation; D054513:Group IV Phospholipases A2; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D008854:Microscopy, Electron; D009206:Myocardium / Q000378:metabolism*; D010101:Oxygen Consumption; D010741:Phospholipases A / Q000096:biosynthesis / Q000235:genetics*; D021241:Spectrometry, Mass, Electrospray Ionization; D014280:Triglycerides / Q000737:chemistry* / Q000378:metabolism
D014280:Triglycerides; D010741:Phospholipases A; D054513:Group IV Phospholipases A2; D002118:Calcium